ES2861440T5 - Use of nucleosome-transcription factor complexes for cancer detection - Google Patents

Use of nucleosome-transcription factor complexes for cancer detection Download PDF

Info

Publication number
ES2861440T5
ES2861440T5 ES17712782T ES17712782T ES2861440T5 ES 2861440 T5 ES2861440 T5 ES 2861440T5 ES 17712782 T ES17712782 T ES 17712782T ES 17712782 T ES17712782 T ES 17712782T ES 2861440 T5 ES2861440 T5 ES 2861440T5
Authority
ES
Spain
Prior art keywords
tissue
cancer
nucleosome
transcription factor
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17712782T
Other languages
English (en)
Spanish (es)
Other versions
ES2861440T3 (es
Inventor
Jacob Vincent Micallef
Jorge Reis-Filho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belgian Volition SPRL
Original Assignee
Belgian Volition SPRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55968658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2861440(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Belgian Volition SPRL filed Critical Belgian Volition SPRL
Publication of ES2861440T3 publication Critical patent/ES2861440T3/es
Application granted granted Critical
Publication of ES2861440T5 publication Critical patent/ES2861440T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES17712782T 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection Active ES2861440T5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1604806.8A GB201604806D0 (en) 2016-03-22 2016-03-22 Method of identifying a cancer of unknown origin
PCT/EP2017/056851 WO2017162755A1 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection

Publications (2)

Publication Number Publication Date
ES2861440T3 ES2861440T3 (es) 2021-10-06
ES2861440T5 true ES2861440T5 (en) 2025-02-05

Family

ID=55968658

Family Applications (2)

Application Number Title Priority Date Filing Date
ES17712782T Active ES2861440T5 (en) 2016-03-22 2017-03-22 Use of nucleosome-transcription factor complexes for cancer detection
ES20210821T Active ES2951136T3 (es) 2016-03-22 2017-03-22 Uso de complejos del factor de transcripción de ADN para la detección del cáncer

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES20210821T Active ES2951136T3 (es) 2016-03-22 2017-03-22 Uso de complejos del factor de transcripción de ADN para la detección del cáncer

Country Status (12)

Country Link
US (1) US20200363418A1 (enExample)
EP (3) EP4270007A3 (enExample)
JP (1) JP6777757B2 (enExample)
KR (2) KR102369544B1 (enExample)
CN (1) CN109313192B (enExample)
AU (1) AU2017238442A1 (enExample)
CA (1) CA3018428C (enExample)
ES (2) ES2861440T5 (enExample)
GB (1) GB201604806D0 (enExample)
MY (1) MY187655A (enExample)
SG (1) SG11201807991QA (enExample)
WO (1) WO2017162755A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
US20240318259A1 (en) * 2021-09-24 2024-09-26 Oncocross Co., Ltd. Method for determining primary tumor site
TW202530419A (zh) 2023-10-04 2025-08-01 比利時商比利時意志有限公司 Pcr方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1274861B1 (en) * 2000-03-27 2009-12-23 Thomas Jefferson University Compositions and methods for identifying and targeting cancer cells
WO2003025583A2 (en) * 2001-09-14 2003-03-27 F. Hoffmann-La Roche Ag Differential diagnosis of disorders of iron metabolism
US7248921B2 (en) * 2003-06-02 2007-07-24 Cameron Health, Inc. Method and devices for performing cardiac waveform appraisal
US20040018525A1 (en) * 2002-05-21 2004-01-29 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma
US20040236188A1 (en) * 2003-05-19 2004-11-25 Ge Medical Systems Information Method and apparatus for monitoring using a mathematical model
US8029989B2 (en) * 2005-08-26 2011-10-04 The Trustees Of The University Of Pennsylvania Method using snail transcriptional repressor
US20090298097A1 (en) * 2007-07-17 2009-12-03 Harris Pamela J Methods for the diagnosis of lung cancer
WO2010001933A1 (ja) * 2008-07-01 2010-01-07 学校法人日本大学 標的遺伝子特異的ヒストン修飾制御剤
MY148542A (en) * 2009-06-15 2013-04-30 Cancer Res Initiatives Foundation A method for the assessment of cancer in a biological sample obtained from a subject
EP2270510A1 (en) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
JP6263474B2 (ja) * 2011-12-07 2018-01-17 シンガポール ボリション ピーティーイー リミテッド ヌクレオソームアダクト検出法
GB201303576D0 (en) * 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for predicting therapy efficacy using nucleosome structure biomarkers

Also Published As

Publication number Publication date
EP3433616B2 (en) 2024-07-24
ES2861440T3 (es) 2021-10-06
EP4270007A3 (en) 2023-12-20
US20200363418A1 (en) 2020-11-19
GB201604806D0 (en) 2016-05-04
KR102369544B1 (ko) 2022-03-03
CA3018428A1 (en) 2017-09-28
CA3018428C (en) 2024-03-19
EP3839513B1 (en) 2023-06-14
CN109313192A (zh) 2019-02-05
EP3839513C0 (en) 2023-06-14
EP3433616A1 (en) 2019-01-30
JP2019510974A (ja) 2019-04-18
EP3433616B1 (en) 2020-12-30
KR102246699B1 (ko) 2021-05-04
SG11201807991QA (en) 2018-10-30
EP3839513A1 (en) 2021-06-23
KR20190013707A (ko) 2019-02-11
AU2017238442A1 (en) 2018-10-11
CN109313192B (zh) 2022-07-26
KR20210049954A (ko) 2021-05-06
EP4270007A2 (en) 2023-11-01
WO2017162755A1 (en) 2017-09-28
MY187655A (en) 2021-10-07
JP6777757B2 (ja) 2020-10-28
ES2951136T3 (es) 2023-10-18

Similar Documents

Publication Publication Date Title
JP6263474B2 (ja) ヌクレオソームアダクト検出法
AU2012300643B2 (en) Method for detecting nucleosomes containing histone variants
ES2951136T3 (es) Uso de complejos del factor de transcripción de ADN para la detección del cáncer
WO2014131845A1 (en) Method for predicting therapy efficacy using nucleosome structure biomarkers
TWI757285B (zh) 癌症偵測方法
HK40055426A (en) Use of dna-transcription factor complexes for cancer detection
HK40003771B (en) Use of nucleosome-transcription factor complexes for cancer detection
HK1249176B (en) Method for detecting nucleosome adducts